FYB206 is being reviewed as a pembrolizumab biosimilar after meeting pharmacokinetic equivalence; no additional efficacy trial is required.
|Articles|August 19, 2014
- Immunotherapy (Issue 3)
- Volume 3
- Issue 1
The Management of Side Effects Associated With Immunotherapies
Author(s)Jedd D. Wolchok, MD, PhD
Jedd D. Wolchok, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the management of side effects associated with immunotherapies.
Advertisement
Jedd D. Wolchok, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the management of side effects associated with immunotherapies.
View more about managing side effects and the limitations of immunotherapies > >
Articles in this issue
about 12 years ago
A Brief History of Immunotherapyabout 12 years ago
Better Biomarker Testing Needed in Immuno-Oncologyabout 12 years ago
Autoimmunity and Limitations of Cancer Vaccinesabout 12 years ago
The Next Wave in Immunotherapy: Combinationsabout 12 years ago
Future Immune Checkpoint StrategiesAdvertisement
Related to this article
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
3
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
4
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
5